Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 14, 2021, titled "Glenmark's subsidiary, lchnos Sciences and Almirall enter into an exclusive LicensingAgreement for First-In-Class IL-lRAP Antagonist Monoclonal Antibody".